The latest research result, the immune score test, can now more accurately define the disease progression of colon cancer patients. According to an international study of more than 2,500 patients, immune scores have been shown to be effective in predicting which patients have a high risk of tumor recurrence and can benefit from intensive treatment after surgery.
Darnaanta kansarka mindhicirka weyn wuxuu u baahan yahay in asal ahaan lagu qiyaaso iyadoo lagu saleynayo faafitaankiisa iyo metastasis-ka xiidanka. Qiyaastan dagaal ee kansarka iyo halista soo noqoshada daaweynta kadib waxay hagaajin doontaa daaweynta. Muddo tobanaan sano ah, waxaa la rumeysnaa in jawaab-celinta difaaca bukaanka ay saameyn wax ku ool ah ku yeelanayso kansarka. Cilmi-baaristii ugu dambeysay waxay muujineysaa in duulaanka burooyinka kansarka ee unugyada difaaca ay noqon karaan tilmaame wanaagsan oo jihada horumarka ah ee kansarka mindhicirka mindhicirka, noqoshada aalad suurtagal ah oo lagu ogaan karo tirada unugyada difaaca jirka ee leh macluumaadka ugu badan ee ku saabsan horumarka cudurka.
Abuuritaanka tijaabadan tijaabada ah waxay ku habboon tahay daaweynta caafimaadka. Waxay ku shaqeysaa iyadoo la cabirayo cufnaanta labada unug ee difaaca jirka ee ku jira burooyinka iyo soohdintooda guud: wadarta unugyada T (CD3 +) iyo unugyada dila ee T (cytotoxic CD8 +). Daraasadani waxay qiimeysay qiimaha saadaalinta bukaanka qaba kansarka weyn ee weyn, oo ay ku jiraan 2681 bukaan oo ka kala yimid xarumo kala duwan. Marka loo eego halista soo noqoshada (5 sano qalliinka ka dib) iyo qiimeynta heerka badbaadada, bukaanada waxaa loo qeybiyay seddex kooxood (heer sare, mid dhexdhexaad ah iyo mid hooseeya) si loo saadaaliyo waxqabadka saadaalinta. Natiijooyinka waxay muujinayaan in bukaanada leh dhibcaha difaaca jirka ay soo bandhigaan halista ugu hooseysa ee soo noqoshada iyo waqtiga badbaadada dheer.
Of the 700 patients, only 8% of patients with high scores relapsed after 5 years. However, the relapse rate of patients with middle and low scores increased significantly, reaching 19% and 32%, respectively. These findings indicate that the immune score provides an accurate and reliable assessment of the risk of colon cancer recurrence. Use the risk of recurrence to improve individual patient treatment strategies, especially changes in chemotherapy regimens. In view of the highly positive results of colon cancer, immunoscore tests for other cancers are under way, which will revolutionize the treatment of cancer patients.
